Patients with the rs1799971 AG genotype may have increased opioid dose requirements as compared to patients with the AA genotype, but decreased opioid dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect opioid dose requirements.